Organ and Tissue Transplantation and Alternatives

Published - Oct 2008| Analyst - Vicki McConnell| Code - HLC012D
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The U.S. market for organ and tissue transplantation and alternatives was worth $18.9 billion in 2007. The market is projected to grow to $20.9 billion in 2008 and $28.2 billion in 2013, representing a compound annual growth rate (CAGR) of 6.1%.
  • The solid organ segment has the largest share of the market, worth $9.7 billion in 2007 and an estimated $10.5 billion in 2008. This is expected to grow at a CAGR of 5.7% to reach $13.8 billion in 2013.
  • Tissue transplantation generated $9.2 billion in 2007. This should increase to $10.4 billion in 2008 and $14.3 billion in 2013, for a CAGR of 6.5%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objective of this study is to provide an in-depth analysis and forecast of the solid organ and tissue transplantation markets. The focus is on products and procedures used or under development for organ and tissue transplantations, including techniques, therapies, drugs, and diagnostics.
 
REASONS FOR DOING THE STUDY
 
Organ transplantation is a dynamic field, with continued progress being made in artificial organs and transplantation methods that reduce rejection and infection. There is increased pressure to perfect transplantation methods because the need for organ donors far outstrips the availability of organs and tissues and governmental regulations have become more stringent. In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option.
 
Despite the lack of organs, the transplantation business continues to innovate through better harvesting and procurement techniques, vastly improved immunosuppression regimes, and advanced tissue matching, which have helped build the organ and tissue transplantation business to a maturing stage. This report will focus on procurement, transplantation by organ, immunosuppressives and other pharmaceuticals, post-transplantation concerns, and alternatives to transplantation. 
Although the organ transplantation business faces tough challenges, it also offers exciting fields of research and tremendous opportunities to meet growing market demand and to cut costs. This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to successfully address it.  
 
INTENDED AUDIENCE 
 
This study provides a thorough background on the structure of the organ and tissue transplantation market and the chief issues it faces. It offers the information needed to understand the current market and to address the emerging one. This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investing consultants, and others interested in the tissue and transplantation market, its products, its participants, and its future.  
 
SCOPE OF REPORT
 
This report offers forecasts by product segment from 2008 through 2013, including supporting analyses for projections.  
 
Product segments covered consist of solid organs (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation market (e.g., bone, skin, cornea, heart valves), along with the pharmaceuticals that accompany each market. Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells. 
 
The arrangement of this report offers an overview of the organ and tissue transplantation market accompanied by analyses and forecasts for each product type and application.
 
International markets are discussed, and information is provided on industry structure and the regulatory environment. Profiles of leading companies involved with tissue transplantation provide information on placement within the market and strategic analyses of the companies available and emerging products.  
 
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.
 
METHODOLOGY
 
Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, transplant surgeons, and pertinent societies and associations representatives. Additional data was derived from companies annual reports and 10Ks, journal articles, prospectus assessments, and government resources. 
 
INFORMATION SOURCES
 
Information for this report was obtained from industry analysts; the Center for Medicare and Medicaid Services (CMS), the National Institutes of Health (NIH), the Centers for Disease Control (CDC) and other government agencies; the United Network for Organ Sharing; the Organ Procurement and Transplantation Network; the Scientific Registry of Transplant Recipients; literature searches; companies annual reports and 10Ks; and product literature.
 
AUTHOR'S  CREDENTIALS
 
Vicki McConnell and Peggy Lehr were the BCC Research co-project directors of this report. Collectively, they have more than 40 years of medical industry experience. Ms. McConnell has written numerous reports and textbook entries on medical equipment components, materials, and manufacturing methods. Ms. Lehr specializes in marketing reports for a variety of industries. Their most recent BCC Research report covered Medical Diagnostic Kits.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Oct-2005| Analyst - Lynn Gray| Code - HLC012C

Report Highlights

  • The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010.
  • The transplantation market is estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%.
  • The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005.
  • The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010.
Published - Mar-2003| Analyst - Peter Downs| Code - HLC012B

Report Highlights

  • Tissue and organ transplantation in the U.S. was a $17.3 billion market in 2002.
  • This is expected to grow 18% to $20.5 billion by 2007 at an average annual rate (AAGR) of 3.5%.
  • The fastest growing sector is small bowel transplantation.
  • Kidney transplantation accounted for 59% of U.S. organ transplants in 2002.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report